Universiteit Leiden

nl en

Leiden Academic Centre for Drug Research

Partnerships

The LACDR represents the core of bio-pharmaceutical research at Leiden University, and we interact closely with our partners:

ULLA

ULLA was founded in 1992 as a European Consortium for (Post Graduate) training in the field of Pharmaceutical Sciences. ULLA takes the name from the cities of the founding universities of the consortium, namely Uppsala, London, Leiden and Amsterdam.

read more 

Collaborations with Chinese universities

LACDR is a very international institute. We have a large network of scientists and institutions all over the world with whom we collaborate in multi-year research programs. Almost half of our PhD students and postdocs are coming from abroad.

In the recent years, LACDR has built strong connections with universities in China. A number of joint research and education programs have been established with top universities, aiming at making a difference in terms of innovation and impact.

A significant number of Chinese PhD candidates have selected LACDR as their institute of choice. They play a very important role in our research program and also participate in the teaching of our Bachelor and Masters students.

Pilot projects progressed well with preferred Chinese partners, facilitating content-driven research collaborations. Together with colleagues from Computer Science and Biology and Leiden Medical Centre, we succeed to establish a unique grant program funded by the Chinese Scholarship Council. Leiden University and Xi'an Jiaotong University were one of the very first consortia to obtain a topic-based CSC program on Artificial Intelligence/Bioscience that will fund 30 CSC PhD positions to be jointly supervised by both sides, over a period of three years.

LACDR encourage the students exchange with China, especially focusing on outgoing students to China. With special programs and funding, Leiden students have been able to explore the drug research in China. LACDR’s student association, Aesculapius, organized a study trip to visit China in 2019, and explored the pharmaceutical study and industry in Shanghai and Nanjing. Following this visit, China Pharmaceutical University (CPU) facilitated a summer school for BFW students from Leiden. 19 BFW students visited Nanjing in August 2019 to follow a varied program of specialized courses at CPU. During these weeks of intense learning, they deepened and broadened their knowledge, at the same time enjoying the Chinese culture and the warm-heartedness of Chinese students.

Researchers from LACDR visit partners in China regularly to carry out joint research projects and other collaborative activities, several of them holds honoury professor/visiting professor/visiting scientists in top Chinese universities.

LACDR is always looking forward to deepen its cooperation with Chinese partner universities, as well new opportunities for partnerships.

Leiden Institute of Chemistry (LIC)

The LIC includes research in Chemistry and Life Sciences. Our environment and quality of life is largely determined by chemistry, so teaching and research at the forefront of molecular and life sciences is of great importance for our future.

read more

Centre for Human Drug Research (CHDR)

The CHDR provides a full range of early stage clinical pharmacology services. CHDR specializes in early proof of pharmacology and in the complex process of drug development, we offer an efficient route towards proof of concept in patients. By conducting highly informative early-phase clinical studies, development risks can be minimized and costs can be reduced.

read more

Leiden University Medical Center (LUMC)

LUMC is a modern university medical center for research, education and patient care with a high quality profile and a strong scientific orientation.

read more 

Paul Janssen Futurelab Leiden

Paul Janssen Futurelab Leiden is an international training program providing blended learning (online and on-campus) to biomedical professionals with an entrepreneurial spirit. Our mission: to teach a new generation of leaders to develop new medical interventions more efficiently and more effectively.

read more

This website uses cookies. More information